Imagenetix reports net loss of $697,000 for fiscal 2010

Imagenetix, Inc. (OTC Bulletin Board: IAGX) announced today results for its fiscal year ended March 31, 2010. Net sales decreased 12% for the year to $6,596,000 from the $7,461,000 reported for the same period last year.  

Gross profit as a percentage of sales decreased to 43% from 46% percent for the prior fiscal year.  This decrease was primarily due to the sales mix, which included increased percentages for advertising allowances for the Company's branded retail products.

Net loss for the year was $697,000 or $.06 per share compared to a net profit of $430,000 or $.04 per share in the prior fiscal year.

Commenting on the results of the year, Mr. William Spencer, Imagenetix Chief Executive Officer said, "We continued to make progress in the mass market segment of our business by expanding the number of stores in which Celadrin® can be purchased.  Activity in wholesale and distribution revenue came in lower which resulted in a year over year reduction in sales and a loss for the current year.  We have already started shipment of Celadrin© to the nation's number one retailer at the start of the new fiscal year and are anticipating solid growth for fiscal 2011. Sales and profit growth are expected to primarily stem from our mass market related sales."

Source:

Imagenetix, Inc.

Posted in:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.